Table 2.
Patient demographics and clinical characteristics at therapy initiation (2004–2015)
| Characteristic | TNFi monotherapy | Other biologic monotherapya | csDMARD monotherapy | TNFi + csDMARD combination therapy | Other biologica + csDMARD combination therapy | Overall |
|---|---|---|---|---|---|---|
| N = 770 | N = 369 | N = 2982 | N = 3022 | N = 884 | N = 8027 | |
| Female, n (%) | 615 (79.9) | 299 (81.0) | 2264 (75.9) | 2330 (77.1) | 703 (79.5) | 6211 (77.4) |
| Age (years), mean (SD) | 53.6 (12.6) | 58.9 (14.1) | 58.1 (13.4) | 56.0 (12.7) | 57.8 (13.0) | 56.9 (13.1) |
| Race, White, n (%) | 635 (82.5) | 311 (84.3) | 2472 (82.9) | 2460 (81.4) | 731 (82.7) | 6609 (82.3) |
| RA duration (years), mean (SD) | 8.8 (9.5) | 11.5 (10.1) | 6.0 (8.4) | 8.4 (9.1) | 10.6 (9.8) | 7.9 (9.2) |
| Number of previous therapies used, mean (SD) | ||||||
| csDMARDs | 1.2 (1.1) | 1.5 (1.1) | 0.9 (0.9) | 1.5 (0.9) | 1.8 (1.0) | ND |
| Biologics | 0.8 (1.0) | 1.6 (1.3) | 0.2 (0.6) | 0.7 (0.9) | 1.6 (1.3) | ND |
| Previous csDMARD use, n (%) | ||||||
| Naïve | 224 (29.1) | 76 (20.6) | 1922 (64.5) | 1748 (57.8) | 459 (51.9) | 4429 (55.2) |
| Experienced | 546 (70.9) | 293 (79.4) | 1060 (35.5) | 1274 (42.2) | 425 (48.1) | 3598 (44.8) |
| CDAI, mean (SD) | 21.4 (14.7) | 25.3 (14.7) | 16.8 (12.9) | 20.8 (14.8) | 24.5 (14.5) | 20.0 (14.4) |
| CDAI categories, n (%) | ||||||
| Remission | 72 (9.6) | 15 (4.2) | 310 (10.7) | 224 (7.6) | 28 (3.2) | 649 (8.3) |
| Low | 112 (14.9) | 36 (10.0) | 753 (25.9) | 582 (19.7) | 103 (11.8) | 1586 (20.2) |
| Moderate | 246 (32.7) | 115 (31.9) | 1017 (35.0) | 976 (33.0) | 308 (35.2) | 2662 (33.9) |
| High | 322 (42.8) | 195 (54.0) | 826 (28.4) | 1178 (39.8) | 437 (49.9) | 2958 (37.7) |
| PGA, mean (SD) | 38.1 (24.2) | 42.6 (23.8) | 28.8 (21.9) | 35.5 (23.7) | 41.2 (22.7) | 34.2 (23.4) |
| mHAQ, mean (SD) | 0.5 (0.5) | 0.6 (0.6) | 0.4 (0.5) | 0.5 (0.5) | 0.6 (0.5) | 0.5 (0.5) |
| Comorbidities, n (%) | ||||||
| Cardiovascular | 58 (7.5) | 42 (11.4) | 246 (8.2) | 250 (8.3) | 110 (12.4) | 706 (8.8) |
| Malignancy | 30 (3.9) | 35 (9.5) | 228 (7.6) | 150 (5.0) | 68 (7.7) | 511 (6.4) |
| Serious infectionb | 29 (3.8) | 38 (10.3) | 138 (4.6) | 130 (4.3) | 90 (10.2) | 425 (5.3) |
| Diabetes | 57 (7.4) | 33 (8.9) | 269 (9.0) | 247 (8.2) | 101 (11.4) | 707 (8.8) |
N = total number of patients in each cohort; n = number of patients with baseline demographic or clinical characteristic
anon-TNFi and tsDMARDs
bNot captured before 2008
CDAI clinical disease activity index, csDMARD conventional synthetic disease-modifying antirheumatic drug, mHAQ modified health assessment questionnaire, ND not determined, PGA physician global assessment, RA rheumatoid arthritis, SD standard deviation, TNFi tumor necrosis factor inhibitor, tsDMARD targeted synthetic disease-modifying antirheumatic drug